 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | budoprutug (TNT119) / Eliem Therap
Enrollment change, Trial withdrawal: Phase 1b/2a in SLE With Budoputug (clinicaltrials.gov) - Oct 16, 2024
P1/2, N=0, Withdrawn, Sponsor: Tenet Medicines
N=40 --> 0 | Not yet recruiting --> Withdrawn
- budoprutug (TNT119) / Eliem Therap
A Phase 1b, Single-Arm, Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), in Primary Membranous Nephropathy (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1635;
Treatment with budoprutug resulted in high rates of serologic and clinical remission, suggesting that CD19-targeted B-cell depletion may be a promising approach to the treatment of primary MN. These findings warrant larger studies to confirm the efficacy of budoprutug in MN.
- || budoprutug (TNT119) / Eliem Therap
New P1/2 trial: Phase 1b/2a in SLE With Budoputug (clinicaltrials.gov) - Aug 26, 2024
P1/2, N=40, Not yet recruiting, Sponsor: Tenet Medicines
- budoprutug (TNT119) / Eliem Therap
Trial completion date, Trial termination: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Apr 22, 2024
P2, N=1, Terminated, Sponsor: Tenet Medicines
These findings warrant larger studies to confirm the efficacy of budoprutug in MN. Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sponsor change
- | budoprutug (TNT119) / Eliem Therap
Enrollment closed, Phase classification, Enrollment change, Trial completion date: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=6, Active, not recruiting, Sponsor: Tenet Medicines
Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sponsor change Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | N=30 --> 6 | Trial completion date: Oct 2023 --> Aug 2024
- | budoprutug (TNT119) / Eliem Therap
Enrollment change, Trial completion date: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Feb 15, 2024
P2, N=1, Active, not recruiting, Sponsor: Tenet Medicines
Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | N=30 --> 6 | Trial completion date: Oct 2023 --> Aug 2024 N=20 --> 1 | Trial completion date: Nov 2023 --> Aug 2024
- || Review, Journal: New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development. (Pubmed Central) - Sep 15, 2023
The diversity of the current pipeline underscores a strong interest in the GABA system as a target for new treatment development in epilepsy. To date, limited clinical data are available for these investigational treatments and further studies are required to assess their potential value in addressing unmet needs in epilepsy management.
- | budoprutug (TNT119) / Eliem Therap
Enrollment closed, Trial completion date, Trial primary completion date: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Jan 13, 2023
P2, N=20, Active, not recruiting, Sponsor: ValenzaBio, Inc.
To date, limited clinical data are available for these investigational treatments and further studies are required to assess their potential value in addressing unmet needs in epilepsy management. Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Nov 2023 --> Jun 2023
- ||| ETX-810 / Eliem Therap
P2a data: $ELYM Phase 2a trial investigating ETX-810 for the treatment of lumbosacral radicular pain (LSRP) did not meet its primary endpoint (Twitter) - Aug 2, 2022
- || ETX-155 / Eliem Therap
$ELYM Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder https://t.co/UvULHPt27Q (Twitter) - Jul 18, 2022
- || budoprutug (TNT119) / Eliem Therap
New P2 trial: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Jul 1, 2022
P2, N=20, Recruiting, Sponsor: ValenzaBio, Inc.
- ||| ETX-810 / Eliem Therap
Trial completion: Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain (clinicaltrials.gov) - Jun 30, 2022
P2, N=148, Completed, Sponsor: Eliem Therapeutics (UK) Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Nov 2023 --> Jun 2023 Recruiting --> Completed
- || ETX-155 / Eliem Therap, ETX-810 / Eliem Therap
Clinical: $ELYM Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs https://t.co/P8JJF3V3Mg (Twitter) - Apr 25, 2022
- ||| ETX-810 / Eliem Therap
Trial completion: Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain (clinicaltrials.gov) - Mar 24, 2022
P2, N=167, Completed, Sponsor: Eliem Therapeutics (UK) Ltd.
Recruiting --> Completed Recruiting --> Completed
- || KRM-81 / RespireRx, Ztalmy (ganaxolone oral) / Marinus
Review, Journal: The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. (Pubmed Central) - Mar 9, 2022
These GABAkines and non-steroid compounds (GRX-917, a TSPO binding site ligand), darigabat (CVL-865), an α2/3/5-preferring GABAkine, SAN711, an α3-preferring GABAkine, and the α2/3-preferring GABAkine, KRM-II-81, bring new therapeutic promise to this highly utilized medicinal target in neurology and psychiatry...KRM-II-81 also produces anxiolytic- and antidepressant-like effects in rodent models. Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to prevent the development of seizure sensitization.
- || ETX-810 / Eliem Therap
Trial completion date, Trial primary completion date: Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain (clinicaltrials.gov) - Jan 19, 2022
P2, N=122, Recruiting, Sponsor: Eliem Therapeutics (UK) Ltd.
Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to prevent the development of seizure sensitization. Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022
- | ETX-810 / Eliem Therap
Trial completion date: Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain (clinicaltrials.gov) - Nov 3, 2021
P2, N=162, Recruiting, Sponsor: Eliem Therapeutics (UK) Ltd.
Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022 Trial completion date: Oct 2021 --> Mar 2022
- || budoprutug (TNT119) / Eliem Therap
Enrollment open: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy (clinicaltrials.gov) - May 12, 2021
P1b/2a, N=30, Recruiting, Sponsor: ValenzaBio, Inc.
Trial completion date: Oct 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- |||| ETX-810 / Eliem Therap
New P2 trial: Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain (clinicaltrials.gov) - Mar 2, 2021
P2, N=122, Recruiting, Sponsor: Eliem Therapeutics (UK) Ltd.
- | ETX-810 / Eliem Therap
New P2 trial: Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain (clinicaltrials.gov) - Dec 29, 2020
P2, N=162, Recruiting, Sponsor: Eliem Therapeutics (UK) Ltd.